Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00219583

Enrollment

460

Registered

2005-09-22

Start date

2004-08-31

Completion date

2005-06-30

Last updated

2012-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ejaculation

Brief summary

Assessment of efficacy and safety UK-390,957.

Interventions

DRUGUK-390,957

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Premature ejaculation as defined by DSM-IV

Exclusion criteria

* History of erectile dysfunction

Design outcomes

Primary

Measure	Time frame
Assessment of efficacy and safety	—

Secondary

Measure	Time frame
Assessment of quality of sexual life	—

Countries

Australia, Austria, Canada, Czechia, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Spain, Sweden, Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026